by Linda A. Johnson
U.S. regulators on Friday approved a birth control gel that works in a new way to prevent pregnancy.
Phexxi—pronounced FECK’-see—comes in an applicator that women insert before intercourse. The gel made by San Diego-based Evofem Biosciences contains lactic acid, citric acid and potassium bitartrate, all of which are common food additives.
The new gel has some similarities to spermicides, which block the entrance to the cervix and slow sperm down. But Phexxi works differently.
The vagina’s pH—a measure of acidity—is usually in the range of 3.5 to 4.5, the level needed to maintain healthy bacteria. Sperm typically raise that to a more hospitable level of 7 to 8. Phexxi keeps it in the usual acidic range, killing the sperm.
Unlike some other contraceptives, it only needs to be taken shortly before sex and it doesn’t contain hormones, which can cause side effects some women can’t tolerate.
The company said Phexxi will have a list price of $250 to $275 for a box of 12 without insurance.
In a study of 1,400 women aged 18 to 35, Phexxi was about 86% effective on average over seven menstrual cycles and a total of more than 34,000 acts of intercourse. That’s a bit better than condoms, spermicides and other on-demand contraceptives.
The Food and Drug Administration approved Phexxi only as a contraceptive, but Evofem said its testing indicates the gel also reduces the risk of infection by gonorrhea and chlamydia. The company plans to start a large patient study by year’s end, then submit results to the agency for approval as a second product, for preventing those infections.
Evofem would market it under a different name, and likely could tout Phexxi as both birth control and a way of helping to help prevent at least some sexually transmitted diseases.
Use of emergency contraceptive pills among Scandinavian women
© 2020 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.
US regulators approve new type of contraceptive gel (2020, May 22)
retrieved 22 May 2020
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
- COVID case rates hit new high for England, study finds - April 7, 2022
- Govt’s focus on affordable healthcare ensured significant savings for poor, middle class: PM Modi - April 7, 2022
- SRL Diagnostics and Skye Air Mobility collaborate to transport pathology samples using drone logistics - April 6, 2022
- Healthineers sets up new production line of CT scanners in Bengaluru under PLI scheme - April 6, 2022
- Lupin inks licensing pact with Alvion to market drugs in Southeast Asia - April 6, 2022
- Yoga Mahotsav: Ayush Ministry to organise event to demonstrate common yoga on World Health Day - April 6, 2022
- LordsMed forays into the medtech space with launch of health ATMs ‘Lords Sehat’ - April 5, 2022
- ‘Friendly viruses’ can be the next big thing in the history of medical research and more - April 5, 2022
- No setback to Bharat Biotech even as WHO suspends Covaxin UN supply: Sources - April 4, 2022
- Govt panel recommends Serum’s Covovax dose for kids aged 12 and above - April 4, 2022